tiprankstipranks
Advertisement
Advertisement

SNY Stock Latest News

Sanofi announces Executive Committee to support next strategic chapter
The FlySanofi announces Executive Committee to support next strategic chapter
6h ago
SNY
Ligand price target raised to $345 from $330 at Craig-Hallum
PremiumThe Fly
Ligand price target raised to $345 from $330 at Craig-Hallum
1d ago
SNY
LGND
Sanofi Wins FDA Nod for First Anticancer Therapy Delivered via On-Body Injector
PremiumCompany Announcements
Sanofi Wins FDA Nod for First Anticancer Therapy Delivered via On-Body Injector
4d ago
6K
SNY
Sanofi announces subcutaneous Sarclisa Escena approved in U.S.
PremiumThe Fly
Sanofi announces subcutaneous Sarclisa Escena approved in U.S.
11d ago
SNY
Sanofi price target lowered to $49 from $52 at Morgan Stanley
PremiumThe Fly
Sanofi price target lowered to $49 from $52 at Morgan Stanley
13d ago
SNY
ARS Pharmaceuticals announces CEO succession
PremiumThe FlyARS Pharmaceuticals announces CEO succession
14d ago
SNY
SPRY
Sanofi’s Nexviazyme Delivers Positive Phase 3 Results in Infantile-Onset Pompe Disease
Premium
Company Announcements
Sanofi’s Nexviazyme Delivers Positive Phase 3 Results in Infantile-Onset Pompe Disease
14d ago
6K
SNY
AI Daily: Amazon’s AWS commits $1B toward new unit
Premium
The Fly
AI Daily: Amazon’s AWS commits $1B toward new unit
21d ago
AZN
BMY
Anthropic takes aim at pharma industry with Claude Science, STAT reports
PremiumThe Fly
Anthropic takes aim at pharma industry with Claude Science, STAT reports
21d ago
AZN
BMY
Sanofi Secures Multiple June Approvals and New R&D Chief to Bolster Oncology and Neurology Push
PremiumCompany Announcements
Sanofi Secures Multiple June Approvals and New R&D Chief to Bolster Oncology and Neurology Push
27d ago
6K
SNY
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
PremiumTipRanks Newswire
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
28d ago
SNY
BIIB
Sanofi’s RSV Study in Queensland: What Real-World Uptake Could Mean for Investors
PremiumCompany Announcements
Sanofi’s RSV Study in Queensland: What Real-World Uptake Could Mean for Investors
28d ago
SNY
MacroGenics to receive $24.5M milestone payment from Sanofi
PremiumThe FlyMacroGenics to receive $24.5M milestone payment from Sanofi
29d ago
SNY
MGNX
Sanofi Wins FDA Accelerated Approval for Tzield in Newly Diagnosed Stage 3 Type 1 Diabetes Children
Premium
Company Announcements
Sanofi Wins FDA Accelerated Approval for Tzield in Newly Diagnosed Stage 3 Type 1 Diabetes Children
29d ago
6K
SNY
Sanofi appoints Paulo Fontoura as Global Head of R&D
Premium
The Fly
Sanofi appoints Paulo Fontoura as Global Head of R&D
29d ago
SNY
Sanofi investors likely to view new R&D head as a positive, says BofA
PremiumThe Fly
Sanofi investors likely to view new R&D head as a positive, says BofA
29d ago
SNY
CHRO
‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition
PremiumMarket News
‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition
30d ago
SNY
ABBV
Sanofi price target lowered to EUR 95 from EUR 100 at Deutsche Bank
PremiumThe Fly
Sanofi price target lowered to EUR 95 from EUR 100 at Deutsche Bank
1M ago
SNY
CMS proposes to lock in lower prices in Medicare drug price negotiation program
PremiumThe Fly
CMS proposes to lock in lower prices in Medicare drug price negotiation program
1M ago
AZN
BMY
Dianthus’ new CAPTIVATE responder rate beat expectations, says Raymond James
PremiumThe FlyDianthus’ new CAPTIVATE responder rate beat expectations, says Raymond James
1M ago
SNY
DNTH
Sanofi Expands Global Employee Share Plan with 2026 Offering
Premium
Company Announcements
Sanofi Expands Global Employee Share Plan with 2026 Offering
1M ago
6K
SNY
Dianthus price target raised to $132 from $110 at Jefferies
Premium
The Fly
Dianthus price target raised to $132 from $110 at Jefferies
1M ago
SNY
DNTH

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >